Monitor ASGCT presentations for detailed efficacy and safety results; successful data could drive stock appreciation, while delays or negative findings would be bearish. Track IND submission in Q2 2026 as a key catalyst.
Price Chart
Executive Summary
Voyager Therapeutics announced eight presentations at ASGCT 2026, headlined by late-breaking oral data on VY1706, a tau-silencing gene therapy for Alzheimer's disease, showing compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs. The company expects to submit an IND in Q2 2026 and initiate first-in-human dosing in H2 2026, marking a key milestone for its TRACER capsid platform.
Key Facts
- Late-breaking oral presentation of 3-month GLP toxicology data for VY1706 in Alzheimer's disease at ASGCT 2026 (May 11-15, 2026)
- Voyager anticipates submitting IND for VY1706 in Q2 2026, with first-in-human dosing projected in H2 2026
- Additional data on capsid innovation for muscular/neuromuscular targeting, immune evasion, and manufacturability
Financial Impact
No financial data disclosed; VY1706 is preclinical and not yet generating revenue.
Risk Factors
- Preclinical data may not translate to clinical success
- IND submission or clinical trial initiation could be delayed
- Alzheimer's gene therapy is a competitive and high-risk space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.02 | awaiting T+60 | — | $1.75 (−13.37%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.75 (−45.99%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.75 (−53.83%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.75 (−57.83%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.75 (−56.79%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.75 (−53.58%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.75 (−57.73%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.70%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers